Date published: 2025-10-11

1-800-457-3801

SCBT Portrait Logo
Seach Input

MEK 162 (CAS 606143-89-9)

0.0(0)
Write a reviewAsk a question

Alternate Names:
5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide
CAS Number:
606143-89-9
Molecular Weight:
441.23
Molecular Formula:
C17H15BrF2N4O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

MEK 162 is a compound that has been the subject of extensive research within the fields of enzymology and signal transduction pathways. In non-clinical research environments, MEK 162 is primarily used to investigate the biochemical mechanisms of the mitogen-activated protein kinase (MAPK) pathway, which is involved in cell proliferation and differentiation. Studies focus on how MEK 162, as a potent inhibitor of MEK1/2 kinases, affects the phosphorylation and activation of downstream proteins such as ERK1/2. Research on MEK 162 includes examining its effects on various cellular processes in vitro, and it serves as a tool to understand the role of the MAPK pathway in cell biology. By inhibiting this pathway, MEK 162 aids in dissecting the signal transduction events that contribute to the regulation of gene expression. Additionally, MEK 162 may be used in the study of kinase-substrate relationships, providing insights into the selectivity and specificity of kinase inhibitors.


MEK 162 (CAS 606143-89-9) References

  1. KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition.  |  Hamidi, H., et al. 2014. Br J Cancer. 111: 1788-801. PMID: 25167228
  2. The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent.  |  Li, C., et al. 2015. Cancer Biol Ther. 16: 34-42. PMID: 25692620
  3. Combination treatment with perifosine and MEK-162 demonstrates synergism against lung cancer cells in vitro and in vivo.  |  Zhang, J., et al. 2015. Tumour Biol. 36: 5699-706. PMID: 25697899
  4. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma.  |  Zhu, YR., et al. 2015. Cancer Biol Ther. 16: 602-9. PMID: 25869769
  5. MEK-ERK inhibition potentiates WAY-600-induced anti-cancer efficiency in preclinical hepatocellular carcinoma (HCC) models.  |  Wang, K., et al. 2016. Biochem Biophys Res Commun. 474: 330-337. PMID: 27107695
  6. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.  |  Lee, MS., et al. 2016. Oncotarget. 7: 39595-39608. PMID: 27167191
  7. Targeting the ERK pathway for the treatment of Cushing's disease.  |  Zhang, D., et al. 2016. Oncotarget. 7: 69149-69158. PMID: 27708250
  8. MEK162 Enhances Antitumor Activity of 5-Fluorouracil and Trifluridine in KRAS-mutated Human Colorectal Cancer Cell Lines.  |  Gong, J., et al. 2017. Anticancer Res. 37: 2831-2838. PMID: 28551618
  9. Anti-tumor effects of NVP-BKM120 alone or in combination with MEK162 in biliary tract cancer.  |  Jin, L., et al. 2017. Cancer Lett. 411: 162-170. PMID: 29024814
  10. Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma.  |  Rose, AAN. 2019. Drugs Today (Barc). 55: 247-264. PMID: 31050693
  11. A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer.  |  Fung, AS., et al. 2021. Lung Cancer. 157: 21-29. PMID: 34052705
  12. Radio-sensitizing effect of MEK inhibition in glioblastoma in vitro and in vivo.  |  Houweling, M., et al. 2023. J Cancer Res Clin Oncol. 149: 297-305. PMID: 36451044

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

MEK 162, 10 mg

sc-488879
10 mg
$306.00